Sickle cell strides
How Bioverativ will tap advances in HSC mobilization for sickle cell therapy BIVV003
Advances in hematopoietic stem cell mobilization procedures have enabled Bioverativ Inc. to bring its enhancer-targeted therapy, BIVV003, into the clinic for sickle cell disease. FDA accepted the IND for BIVV003 on Wednesday, and the company expects to start Phase I/II testing this year.
Under a 2014 deal